According to a new report by Polaris Market Research, the global psoriasis drug market was valued at USD 22.63 billion in 2025 and is projected to reach USD 56.96 billion by 2034, expanding at a CAGR of 10.80% over the forecast period. Growth is underpinned by the rising global prevalence of psoriasis, advancing biologic and biosimilar therapies, and growing awareness of treatment alternatives across key end-use markets.

What Is Driving Psoriasis Drug Market Growth?

Demand is climbing as the global psoriasis burden — affecting an estimated 125 million people worldwide, according to the International Federation of Pharmaceutical Manufacturers and Associations — converges with expanding biologic drug approvals, pushing treatment adoption across dermatology clinics. Manufacturers are prioritizing IL-23/IL-17 targeted mechanisms, with Polaris analysts noting that biosimilar access positions the segment for sustained double-digit growth through 2034, with interleukin inhibitors emerging as the largest revenue contributor and parenteral biologics posting the fastest incremental gains.

Key Trends Shaping the Psoriasis Drug Industry

IL-23/IL-17 Biologics and Biosimilars

Interleukin inhibitors have demonstrated up to 90% improvement in Psoriasis Area and Severity Index scores, reflecting strong technology advancement, while biosimilar approvals are improving affordability across developing regions.

Precision Dermatology and Treatment Sequencing

Genomic and pharmacogenomic profiling is enabling tailored treatment selection, strengthening the market outlook for personalized psoriasis care and improving long-term disease control.

Targeted Oral Therapies and TYK2 Inhibitors

Next-generation oral treatments, including TYK2 inhibitors and non-steroidal topicals, are expanding options for patients who prefer non-injectable regimens, reshaping the competitive landscape beyond biologics alone.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/global-psoriasis-drug-market 

Market Segmentation: Breaking Down the Psoriasis Drug Market

Polaris segments the psoriasis drug market by class, treatment modality, route of administration, distribution channel, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Class

The Interleukin Inhibitors segment held the largest share at 38.9% in 2025 and is also posting the highest growth rate, owing to targeted action mechanisms in managing moderate-to-severe psoriasis. Vitamin D analogues and corticosteroids remain vital for mild-to-moderate cases and combination regimens.

By Treatment

The Biologics segment led with a 62.8% share in 2025, driven by advanced mechanisms targeting specific immune pathways. Topical treatments remain integral for mild cases, while systemic oral drugs continue serving patients preferring non-injectable options.

By Route of Administration

The Parenteral segment held the largest share and is projected to grow at approximately 11.2% CAGR through 2034, supported by pre-filled syringes and auto-injectors that improve patient-friendly biologic delivery.

By Region

North America led with a 44.5% share in 2025, backed by high psoriasis prevalence and robust biologic adoption. Asia Pacific is projected to grow at approximately 10.6% CAGR through 2034 as healthcare expenditure rises.

Regional Outlook: Where Is Psoriasis Drug Growing Fastest?

North America led the market in 2025 on the back of advanced healthcare infrastructure and favorable reimbursement policies, while Asia Pacific is expected to post the fastest CAGR through 2034, driven by rising prevalence in China and India. Within North America, the U.S. remains the largest single market; within Europe, Germany, the UK, and France lead adoption. Europe rounds out the top three, supported by strong biologics and biosimilars research investment.

Competitive Landscape: Leading Psoriasis Drug Companies

Key players profiled in the report include AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., Novartis AG, and Eli Lilly and Company, who are focusing on label expansions and biosimilar development to strengthen market position across the Interleukin Inhibitors and Biologics segments outlined above. Recent moves include AbbVie's June 2026 European Commission approval of Skyrizi for pediatric plaque psoriasis and Johnson & Johnson's March 2026 FDA approval of ICOTYDE, a first-line oral IL-23 receptor antagonist, both aimed at deepening share across North America and Europe.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching psoriasis treatment options, this report benchmarks market share, segment-level pricing, and forecast data — by class, treatment, route, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking oral targeted therapies as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Nickel Cadmium Battery Market

Omega 3 Supplements Market

Maternity Innerwear Market

Bulk Filtration Market

Flow Computer in Oil & Gas Market

Flow Computer in Oil & Gas Market

Carbon Tape Market

Aluminum Curtain Wall Market

Cashew Nutshell Liquid Market